IN2012DN00871A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00871A IN2012DN00871A IN871DEN2012A IN2012DN00871A IN 2012DN00871 A IN2012DN00871 A IN 2012DN00871A IN 871DEN2012 A IN871DEN2012 A IN 871DEN2012A IN 2012DN00871 A IN2012DN00871 A IN 2012DN00871A
- Authority
- IN
- India
- Prior art keywords
- hydrogen
- group
- alkyl
- substituent group
- carbocyclic
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000003918 triazines Chemical class 0.000 abstract 2
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The triazine compounds are of formula (I) wherein: R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when R1 is hydrogen or =NH when R1 is a substituent group; R3 and R4 are both carbocyclic, heterocyclic or alkyl groups and may be same or different; and R5 is hydrogen, alkyl or a cyclic aryl group, with the proviso that: when R3 and R4 are both alkyl they are linked to form a cycloalkyl group, and R5 is a cyclic aromatic group; and when R3 and R4 are both carbocyclic or heterocyclic groups, R5 is hydrogen or an alkyl group; or a salt thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0911993A GB2471713A (en) | 2009-07-08 | 2009-07-08 | 1,2,4-triazine derivatives and their use as sodium channel blockers |
PCT/GB2010/051127 WO2011004196A1 (en) | 2009-07-08 | 2010-07-08 | Cyclic triazo sodium channel blockers |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN00871A true IN2012DN00871A (en) | 2015-07-10 |
Family
ID=41022452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN871DEN2012 IN2012DN00871A (en) | 2009-07-08 | 2010-07-08 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8748600B2 (en) |
EP (1) | EP2451807B1 (en) |
JP (1) | JP5847079B2 (en) |
KR (1) | KR20120048593A (en) |
CN (1) | CN102482266B (en) |
AU (1) | AU2010269982B2 (en) |
CA (1) | CA2767298A1 (en) |
ES (1) | ES2550052T3 (en) |
GB (1) | GB2471713A (en) |
IL (1) | IL217330B (en) |
IN (1) | IN2012DN00871A (en) |
WO (1) | WO2011004196A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0800741D0 (en) * | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
GB2471729A (en) * | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
JP2018524302A (en) * | 2015-06-12 | 2018-08-30 | ユニバーシティ オブ グリニッジ | Triazine derivatives as interferon-gamma inhibitors |
KR20180122406A (en) | 2016-03-14 | 2018-11-12 | 애퍼런트 파마슈티컬스 인크. | Pyrimidine and its variants, and uses thereof |
MX2018011622A (en) * | 2016-03-25 | 2019-03-28 | Afferent Pharmaceuticals Inc | Pyrimidines and variants thereof, and uses therefor. |
JP6679093B1 (en) * | 2018-11-26 | 2020-04-15 | 大学共同利用機関法人自然科学研究機構 | Method for screening inhibitor and therapeutic agent targeting functional inhibition of sodium channel and acid-sensitive ion channel and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3637688A (en) * | 1970-01-09 | 1972-01-25 | American Home Prod | 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines |
ZA803250B (en) | 1979-06-01 | 1982-01-27 | Wellcome Found | Substituded aromatic compounds |
GB8328757D0 (en) * | 1983-10-27 | 1983-11-30 | Wellcome Found | Chemical compounds |
DE10134980C2 (en) * | 2001-07-17 | 2003-05-28 | Helm Ag | Process for the preparation of lamotrigine |
GB0613836D0 (en) * | 2006-07-13 | 2006-08-23 | Univ Greenwich | New medical use of triazine derivatives |
GB0800741D0 (en) * | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
-
2009
- 2009-07-08 GB GB0911993A patent/GB2471713A/en not_active Withdrawn
-
2010
- 2010-07-08 ES ES10732408.9T patent/ES2550052T3/en active Active
- 2010-07-08 AU AU2010269982A patent/AU2010269982B2/en not_active Ceased
- 2010-07-08 US US13/382,741 patent/US8748600B2/en active Active
- 2010-07-08 IN IN871DEN2012 patent/IN2012DN00871A/en unknown
- 2010-07-08 JP JP2012519066A patent/JP5847079B2/en not_active Expired - Fee Related
- 2010-07-08 WO PCT/GB2010/051127 patent/WO2011004196A1/en active Application Filing
- 2010-07-08 EP EP10732408.9A patent/EP2451807B1/en not_active Not-in-force
- 2010-07-08 CA CA2767298A patent/CA2767298A1/en not_active Abandoned
- 2010-07-08 CN CN201080030801.2A patent/CN102482266B/en not_active Expired - Fee Related
- 2010-07-08 KR KR1020127002940A patent/KR20120048593A/en not_active Application Discontinuation
-
2012
- 2012-01-02 IL IL217330A patent/IL217330B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GB2471713A (en) | 2011-01-12 |
CA2767298A1 (en) | 2011-01-13 |
CN102482266A (en) | 2012-05-30 |
AU2010269982A1 (en) | 2012-02-16 |
AU2010269982B2 (en) | 2015-05-14 |
IL217330A0 (en) | 2012-02-29 |
WO2011004196A1 (en) | 2011-01-13 |
GB0911993D0 (en) | 2009-08-19 |
US8748600B2 (en) | 2014-06-10 |
CN102482266B (en) | 2015-07-08 |
EP2451807B1 (en) | 2015-09-02 |
US20120135993A1 (en) | 2012-05-31 |
ES2550052T3 (en) | 2015-11-04 |
KR20120048593A (en) | 2012-05-15 |
JP2012532858A (en) | 2012-12-20 |
JP5847079B2 (en) | 2016-01-20 |
IL217330B (en) | 2018-12-31 |
EP2451807A1 (en) | 2012-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN00871A (en) | ||
MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
UA99637C2 (en) | Pyridine derivative substituted with heterocycle and phosphonoxymethyl group and antifungal agent containing the same | |
CY1118572T1 (en) | CYCLOGAL PRODUCTION | |
TW200738684A (en) | Novel sulfated cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
WO2008108380A3 (en) | Pyrrole compounds | |
TW201129556A (en) | Novel antiplatelet agent | |
MX2010009736A (en) | Heterocyclic compound. | |
BRPI0813244B8 (en) | compounds derived from pyrazinone, compositions comprising said compounds, use of the compounds in the treatment of lung diseases and intermediate compound | |
JO3007B1 (en) | Compounds and compositions as protein kinase inhibitors | |
GEP201706728B (en) | Noxious organism control agent | |
MX2010005649A (en) | Novel compounds as cannabinoid receptor ligands and uses thereof. | |
MY186165A (en) | New bicyclic dihydroquinoline-2-one derivatives | |
MX343225B (en) | New aryl-benzocycloalkyl amide derivatives. | |
MY169043A (en) | New dihydroquinoline-2-one derivatives | |
TW200738685A (en) | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
MX2012007582A (en) | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds. | |
MX2012006026A (en) | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections. | |
MX2016001855A (en) | Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection. | |
MX2015000903A (en) | Carbamate/urea derivatives. | |
PH12014501181A1 (en) | N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics | |
MX2010002007A (en) | Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors. | |
TW200745048A (en) | Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors | |
MX2015000163A (en) | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection. | |
EA201390374A1 (en) | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DISORDERS CAUSED BY FACILITATED BY NEUROTREMISSION OF SEROTONIN, NOREPINEFRIN OR DOPAMINE |